Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 14
Submit an article Journal homepage
197
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Risk of second primary malignancy in patients with primary myelofibrosis: a SEER database study

Utsav Joshia Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8251-5846
ORCID Icon,
Adheesh Bhattaraib Department of Internal Medicine, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
,
Suman Gairec Department of Internal Medicine, Mount Sinai Hospital, Chicago, IL, USA
,
Simrat Gilla Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA
,
Vishakha Agrawalb Department of Internal Medicine, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
,
Sumeet Kumar Yadavd Department of Hospital Internal Medicine, Mayo Clinic Health System, Mankato, MN, USA
,
Soon Khai Lowa Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA
,
Prajwal Dhakale Department of Internal Medicine, Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA, USAORCID Iconhttps://orcid.org/0000-0002-2368-1510
ORCID Icon,
Vijaya Raj Bhattf Department of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA;g Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA
&
Peter A. Kouidesh Division of Hematology and Clinical Oncology, Rochester General Hospital, Rochester, NY, USA;i University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
 show all
Pages 3456-3461 | Received 09 Jun 2022, Accepted 04 Sep 2022, Published online: 18 Sep 2022

References

  • American Cancer Society. Cancer treatment & survivorship facts & figures 2019–2021; [cited 2022 May 8]. Available from: https://www.cancer.org/research/cancer-facts-statistics/survivor-facts-figures.html
  • Morton LM, Onel K, Curtis RE, et al. The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am Soc Clin Oncol Educ Book. 2014;34:e57–e67.
  • Brabrand M, Frederiksen H. Risks of solid and lymphoid malignancies in patients with myeloproliferative neoplasms: clinical implications. Cancers. 2020;12(10):3061.
  • Brunner AM, Hobbs G, Jalbut MM, et al. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. Leuk Lymphoma. 2016;57(5):1197–1200.
  • Song IC, Yeon SH, Lee MW, et al. Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm. Blood Res. 2022;57(1):59–68.
  • Barraco F, Greil R, Herbrecht R, et al. Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis. Br J Haematol. 2020;191(5):764–774.
  • Khanal N, Giri S, Upadhyay S, et al. Risk of second primary malignancies and survival of adult patients with polycythemia vera: a United States population-based retrospective study. Leuk Lymphoma. 2016;57(1):129–133.
  • Shrestha R, Giri S, Pathak R, et al. Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia. World J Clin Oncol. 2016;7(4):324–330.
  • Hong J, Lee JH, Byun JM, et al. Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms. Blood Adv. 2019;3(22):3700–3708.
  • Landtblom AR, Bower H, Andersson TML, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia. 2018;32(10):2203–2210.
  • Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020;136(1):61–70.
  • Vallapureddy RR, Mudireddy M, Penna D, et al. Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer J. 2019;9(2):12.
  • Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer. 2008;112(12):2726–2732.
  • Yogarajah M, Tefferi A. Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome. Mayo Clin Proc. 2017;92(7):1118–1128.
  • Passamonti F, Rumi E, Elena C, et al. Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. Br J Haematol. 2010;150(6):719–721.
  • Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861–1869.
  • Begna K, Abdelatif A, Schwager S, et al. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience. Blood Cancer J. 2016;6(5):e427.
  • Pepe S, Rossi E, Trawinska M, et al. Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN Latial Group. Ann Hematol. 2022;101(6):1275–1282.
  • Sekhri R, Sadjadian P, Becker T, et al. Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies. Ann Hematol. 2021;100(11):2707–2716.
  • Blechman AB, Cabell CE, Weinberger CH, et al. Aggressive skin cancers occurring in patients treated with the Janus kinase inhibitor ruxolitinib. J Drugs Dermatol. 2017;16(5):508–511.
  • Pettersson H, Knutsen H, Holmberg E, et al. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. Eur J Haematol. 2015;94(2):152–156.
  • Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021;71(3):209–249.
  • Donin NM, Filson CP, Drakaki A, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer. 2016;122(19):3075–3086.
  • Szuber N, Vallapureddy RR, Penna D, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018;93(12):1474–1484.
  • Polverelli N, Elli EM, Abruzzese E, et al. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2021;193(2):356–368.
  • Hansen IO, Sørensen AL, Hasselbalch HC. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. Eur J Haematol. 2017;98(1):75–84.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.